Recent reports have shown that the gut microbiome can affect systemic immunity and promote autoimmune diseases. This provides new ideas for the treatment of rheumatoid arthritis (RA) that next-generation probiotics (NGPs) may be useful. Creative Biolabs has been devoted to the development of NGPs for years. With the comprehensive technology platform and Ph.D. level scientists, we are capable of providing global researchers with high-quality NGPs development services.
RA is an autoimmune systemic inflammatory disease. In most patients, it leads to joint destruction and functional disability due to the disease targeting the self-antigens present in the synovium, cartilage, and bone. Substantial insights into RA pathophysiology suggest that various inflammatory pathways lead to an altered immune system and onset of disease. The gut microbiome is involved in maintaining immune homeostasis and acts as an indicator of the health status of the host. Perturbation of this interaction can affect mucosal as well as systemic immunity, and promote various inflammatory and autoimmune diseases. Consequently, attempts have been made to define the beneficial microbes and their metabolites for their use in treating RA.
Fig.1 A schematic representation of intestinal dysbiosis in rheumatic autoimmune diseases in humans. (de Oliveira, 2017)
The triggering of RA involves the interaction of HLA genes and environmental factors, such as smoking and infections. Among environmental factors, dysbiosis has been identified as a possible trigger factor for autoimmunity and RA development. Increasing evidence suggests an association between intestinal dysbiosis and rheumatic diseases and their role in disease progression and the inflammatory microenvironment. Thus NGPs treatment becomes a potential candidate for novel RA therapy exploration.
Administration of probiotic strain L. rhamnosus recovered the Bacteroidetes and Verrucomicrobia abundance which was lost in rats fed with a high-fat diet. Moreover, the administration of the lactobacillus probiotic strain led to a decrease in the abundance of Firmicutes, which was increased in the rats on a high-fat diet. At a lower taxonomic level, the numbers of escherichia and shigella were suppressed, whereas the numbers of Lactobacillus spp. were increased. Such modulations might be beneficial for host health, as escherichia and shigella are considered harmful and lactobacillus taxa are considered probiotic.
F. prausnitzii is present in abundance in a healthy gut and is one of the main butyrate producers. Probiotic therapy with F. prausnitzii could help suppress inflammation, as it produces high amounts of butyrate and leads to the production of IL-10, an anti-inflammatory cytokine.
Several studies have reported an association between periodontal disease, Porphyromonas gingivalis, and RA. Antibodies to P. gingivalis were more common in RA subjects than controls, suggesting a pathogenic role in RA. Probiotic therapy of Bifidobacterium adolescentis might be helpful in this case, as this bacterium competes with P. gingivalis by reducing vitamin K concentration.
Creative Biolabs has been devoted to offering NGPs development services for years and has accomplished many projects. With extensive industrial experience, our scientists are confident in providing satisfied NGPs development services to global researchers. Our services at Creative Biolabs include but not limited to:
As an industry-leading company, Creative Biolabs has established a comprehensive NGPs development platform. With years of industrial experience and excellent scientists specialized in probiotics, we provide high-quality NGPs development services to help global researchers with the exploration of novel RA therapeutic methods.
If you are interested in our services, please feel free to contact us.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.